Drugs / S1 [arm: experimental] — S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimer
S1 [arm: experimental] — S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimer
also known as
S-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05228743 | Sep 2020 → Aug 2023 | gastric cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S1 [arm: experimental] — S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05228743 ↗ |
| Known as | S-1 | “S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug that is converted to fluorouracil, mainly in liver microsomes but also in tumour tissue), gimeracil (an...” NCT05228743 ↗ |
| Modality | Small molecule | “S-1 is an oral fluoropyrimidine” NCT05228743 ↗ |
| Route | Oral | “S-1 is an oral fluoropyrimidine” NCT05228743 ↗ |